Immuneering Corporation (IMRX) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Immunering Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we would ask for a limit of one question and one follow-up question per person. To ask a question at that time, please press star followed by 11 on your touchtone phone. As a reminder, this call is being recorded today, Monday, March 6, 2023. I would now like to turn the conference over to Lawrence Watts of Gilmartin Group. Please go ahead. Thank you, operator. Joining us on the call today from Immuneering are Chief Executive Officer Ben Ziskins, Chief Scientific Officer Brett Hall, Chief Medical Officer Scott Barrett, and Vice President of Finance and Treasurer, Mallory Morales. During this conference call, management will make forward-looking statements, including statements relating to guidance and timing of data readouts for IMM 1.104 and IND submission of IMM 6.415. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the company describes in the section titled Risk Factors on our annual report on Form 10-K filed with the SEC today, March 6, 2023. Immuneering undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its...